Study of Cytotoxicity of Spiro-Fused [3-Azabicyclo[3.1.0]hexane]oxindoles and Cyclopropa[a]pyrrolizidine-oxindoles Against Tumor Cell Lines
<b>Background</b>: A series of spiro-fused heterocyclic compounds containing cyclopropa[a]pyrrolizidine-2,3'-oxindole and 3-spiro[3-azabicyclo[3.1.0]-hexane]oxindole frameworks were synthesized and studied for their in vitro antiproliferative activity against human erythroleukemia (K562), cervical carcinoma (HeLa), acute T cell leukemia (Jurkat), melanoma (Sk-mel-2) and breast cancer (MCF-7) as well as mouse colon carcinoma (CT26) cell lines. <b>Methods</b>: Cell proliferation was evaluated in vitro by MTS assay. Confocal microscopy was used to study actin cytoskeleton structure and cell motility. Cell cycle analysis was evaluated by flow cytometry. <b>Results</b>: It was found that compounds <b>4</b>, <b>8</b>, <b>18</b> and <b>24</b> showed antiproliferative activity against the Jurkat, K-562, HeLa and Sk-mel-2 cell lines with IC<sub>50</sub> ranging from 2 to 10 μM (72 h). Evaluation of the impact on cell cycle progression showed that the tested compounds achieved significant cell-cycle perturbation with a higher accumulation of cells in the SubG1 and G0/G1 phases of the cell cycle, in comparison to the negative control. I Incubation with tested compounds led to the disappearance of stress fibers (granular actin was distributed diffusely in the cytoplasm in up to 38% of treated HeLa cells) and changes in the number of filopodia-like deformations (reduced from 93% in control cells to 64% after treatment). The impact on the Sk-mel-2 cell actin cytoskeleton structure was even greater: granular actin was distributed diffusely in the cytoplasm in up to 90% of treated cells while the number of filopodia-like deformations was reduced by up to 23%. A scratch test performed on the human melanoma cell line showed that these cells did not fill the scratched strip and lose their ability to move under treatment. <b>Conclusions</b>: The obtained results support the antitumor effect of the tested spiro-compounds and encourage the extension of this study in order to improve their anticancer activity as well as reduce their toxicological risks.
Authors
- Anton A. Kornev
- Alexander V. Stepakov (ORCID: https://orcid.org/0000-0001-6551-0042)
- Stanislav V. Shmakov (ORCID: https://orcid.org/0000-0002-9658-5036)
- Vitali M. Boitsov (ORCID: https://orcid.org/0000-0002-4857-2046)
- Alexander I. Ponyaev
Institutions
- Saint Petersburg Academic University (RU)
- St Petersburg University (RU)
- St. Petersburg State Technological Institute (RU)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-11-25
- DOI
- https://doi.org/10.3390/ph17121582
- Citations
- 6
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Ministry of Education and Science of the Russian Federation